Replies to post #260481 on Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

Petemantx,

Understood. I’m not familiar with start up bio’s that need ~12,000 sf of space. From my experience, lab work needs not a lot of space. Manufacturing, on the other hand, does, depending on the output(I suspect a General Motors plant may require a larger footprint than Table Talk Pies). 100 Vehicles require more space than 100 pies, and 100 pies require more space than 100 pills.

Steve Jobs(and Bill Gates I believe) started in a garage.

Idk, hopefully they’ve leased out the lab space as you’ve noted. I know they declared last year that they were looking for smaller office space. I emailed management, at that time, that I have a close relative affiliated with MAJOR commercial real estate development firm in Boston and offered ipix their ear-to no response.

Last I spoke with the captain was last October, and will say he tolerated my voiced frustrations, suggesting at the end of our discussion that I call back in a week. I never called back as the sp continued to slide, and sits quite below the day of our last talk.

I know-let’s hope.

Imo

[frrol]

The lease is probably a typical one where they can sublet space with landlord approval. There is no sublet disclosure nor evidence of subletting in the cash flow statements. There are also costs for subletting space and time commitments and constraints. It is not what you want to see a young biotech doing with its lab space, you want to see them using it (like you don't want to see layoffs and founder departures). There's no dot to connect or grand insight. We can't afford the space and have few options.

Sub-leasing the lab space is one of management's least concerns of course. They're working on getting a licensing deal for B-OM. From the PRs, it sounds like we still have some interested pharmas, likely in Europe. There's been little selling (or buying) of IPIX in the market so it appears the MFO is holding onto its shares. They would not have not-public knowledge unless the company put one of its principals on our board, which they have not according to SEC filings. But I suspect they are getting 'reassurances' from management, as did Aspire (who eventually demanded milestones, then gave up on us).

The last of the three vital milestones Aspire imposed on us it's still possible: a B deal. The new investors here should focus on that and ignore the noise and "dot-connecting that we have a deal." There is no deal unless one is announced. The next big required and objective disclosure will be the 10Q in early May. Hopefully we'll hear something substantive before then. But the company is still operating, which is a really good thing.